Orthocell boss Paul Anderson has heralded the first surgical use of its Remplir nerve repair device in the US as a “significant milestone”.
Orthocell boss Paul Anderson has heralded the first surgical use of its Remplir nerve repair device in the US as a “significant milestone”.
The Murdoch-based regenerative medicine company told the market the surgery in question was undertaken overnight in an Ohio-based hospital – with the collagen wrap used to repair a foot nerve-based injury.
Friday’s update follows on news back in April that Remplir’s FDA clearance had been approved quicker than Orthocell had anticipated.
Mr Anderson said the development was significant, given the company aims to play a significant role in the $US1.6 billion nerve repair market.
“It signals the start of our commercial journey in the world’s largest healthcare and nerve repair markets, and reflects our commitment to delivering innovative, clinically proven solutions to surgeons and their patients,” he said.
“A critical first step in the US starts with getting Remplir into surgeons’ hands for them to gain familiarity with its key features and benefits in clinical practice.
“These early cases play an important broader strategic role in building experience and knowledge amongst the surgical community.
“We are confident our efforts in the US are on track to drive material growth in sales of Remplir during the second half of calendar 2025.”
As of 12.20pm AWST, Orthocell shares were up 4 per cent to $1.26.
